期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

乳腺癌ER与FES-PET 被引量：7

Estrogen Receptor and Fluoroestradiol-Positron Emission Tomography in Breast Cancer
下载PDF
导出
摘要 雌激素受体(ER)是乳腺癌发生、发展最为重要的分子生物学标志物,其状态在乳腺癌的预后、临床治疗策略、内分泌治疗疗效预测等方面具有非常重要的临床价值。当前ER状态测定方法以肿瘤标本免疫组化法为代表,但均为有创、离体测定,存在取材等诸多因素影响和限制,临床内分泌治疗疗效的预测也远不够完美。FES是一种雌激素类似物,能够特异地与雌激素受体结合,FES-PET能够有效表达肿瘤ER的生物活性,采用标准摄取值客观定性、定量分析。FES-PET与病理测定结果密切相关,能有效评估乳腺癌原发灶及转移灶ER状态,并预测内分泌治疗疗效,有望成为临床无创测定肿瘤ER状态的有效方法。
作者 陈道宝 杨红健
机构地区 浙江省肿瘤医院
出处 《中国肿瘤》 CAS 2008年第7期588-592,共5页 China Cancer
关键词 乳腺肿瘤 雌激素受体 FES 正电子发射断层
分类号 R737.9 [医药卫生—肿瘤]
  • 相关文献

参考文献30

  • 1Althuis MD, Fergenbaum JH, Garcia-Closas MG. Etiology of hormone receptor-defined breast cancer:A systematic leview of the literature [J]. Cancer Epidemiol Biomarkers Prey, 2004, 13(10):1558-1568.
  • 2Early Breast Cancer Trialst's Collaborative Group (EBCTCG).Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of randomized trials[J]. Lancet, 2005, 365(9472): 1687-1717.
  • 3Coates AS, Keshaviah A, Thtirlimann B, et al. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98[J]. J Clin Oncol, 2007, 25(5):486-492.
  • 4Forbes JF, Cuzick J, Buzdar A, et al. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial[J]. Lancet Oncol, 2008, 9(1):45-53.
  • 5江泽飞,宋三泰,刘晓晴,黄长江,李彦博,徐建明,王志坚,汤仲明.369例ER阳性乳腺癌辅助内分泌治疗的前瞻性临床研究[J].中华肿瘤杂志,2001,23(5):420-422. 被引量：13
  • 6Mouridsen H, Gershanovich M, Sun Y, et al. Superior efficacy of letrozole verus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: result of a phase Ⅲ study of the international Letrozole Breast Cancer Group [J]. J Clin Oncol, 2001, 19(10): 2596-2606.
  • 7Fisher B, Wang J, Bryant J, et al. Pathobiology of preoperative chemotherapy: finding from the National Surgical Adjuvant Breast and Bowel (NSABP) protocol B-18 [J]. Cancer, 2002, 20(12):2905-2907.
  • 8Bear HD, Anderson S, Smith RE. Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Project protocol B-27[J]. J Clin Oncol, 2006, 24(13):2019.
  • 9Jordan VC. Tamoxifen: a most unlikely pioneering medicine[J]. Nat Rev Drug Discov, 2003, 2(3):205-213.
  • 10Gradishar WJ. Recently initiated studies: neoadjuvant treatments in next century[J]. Semin Oncol, 1999, 26(1 Suppl 3):26-29.

二级参考文献28

  • 1朱丽萍,波拉提,倪多.新辅助化疗在乳腺癌保乳手术中的应用[J].临床肿瘤学杂志,2005,10(3):308-309. 被引量：5
  • 2张保宁,邵志敏,乔新民,李波,姜军,杨名添,王水,宋三泰,张斌,杨红健.中国乳腺癌保乳治疗的前瞻性多中心研究[J].中华肿瘤杂志,2005,27(11):680-684. 被引量：247
  • 3杨玲,李连弟,陈育德,D.M.Parkin.中国乳腺癌发病死亡趋势的估计与预测[J].中华肿瘤杂志,2006,28(6):438-440. 被引量：278
  • 4Scholl SM, Fourquet A, Asselain B, et al. Neoadjuvant versus adjuvant chemotherapy in premenopausal patients with tumors considered too large for breast conserving surgery:prellminary results of a randornised trial[J]. Eur J Cancer, 1994,30:645-652.
  • 5Biersack HJ, Bender H, Palmedo H. FDG-PET in monitoring therapy of breast cancer[J]. Eur J Nucl Med Mol Imag,2004,31. 112-117.
  • 6Eubank WB, Mankoff DA. Evolving role of positron emission tomography in breast cancer imaging [ J ]. Semin Nucl Med,2005, 35: 84-99.
  • 7Bellon JR, Livingston RB, Eubank WB, et al. Evaluation of the internal mammary lymph nodes by FDG-PET in locally advanced breast cancer ( LABC ) [ J ]. Am J Clin Oncol, 2004, 27 : 407-410.
  • 8Dietl B, Marienhagen J. The therapeutic impact of (18)F-FDG whole body PET: a radiooncologist's view [ J ]. Nuklearmedizin,2005, 44: 8-14.
  • 9Schelling M, Avril N, Nahrig J, et al. Positron emission tomography using [( 18 ) F] Fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer [J]. J Clin Oncol, 2000, 18:1689-1695.
  • 10Jansson T, Westlin JE, Ahlstrom H, et al. Positron emission tomography studies in patients with locally advanced and/or metastatic breast cancer:a method for early therapy evaluation [ J ] ? J Clin Oncol, 1995, 13: 1470-1477.

共引文献72

同被引文献112

  • 1江泽飞,徐兵河,宋三泰,孙燕.乳腺癌内分泌治疗的基本共识[J].中华肿瘤杂志,2006,28(3):238-239. 被引量：48
  • 2穆殿斌,王绍平,杨文锋,付政,陈绪霞,孙晓蓉,于金明.食管癌组织中葡萄糖转运蛋白1表达和Ki-67抗原标记指数与PET／CT显示的^18F-FDG摄取水平相关[J].中华肿瘤杂志,2007,29(1):30-33. 被引量：22
  • 3Coates AS, Keshaviah A, Thurlimann B, et al. Five years of letrozole eompared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast eaneer: update of study BIG1-98 [J]. J Clin Oneol, 2007,25(5) :486-492.
  • 4Jordan VC. Tamoxifen: a most unlikely pioneering medicine [J]. Nat Rev Drug Diseov,2003,2(3):205-213.
  • 5Badoual A, Maruanic C, Ghorra, et al. Pathological prognos tic factors of invasive breast carcinoma in ultrasound-guided large core biopsies-correlation with subsequent surgical excisions[J]. The Breast, 2005,14 (1) : 22-27.
  • 6Baqai T, Shousha S. Oestrogen receptor negativity as a marker for highgrade ductal carcinoma in situ of the breast[J]. Histopathology, 2003,42(5) : 440-447.
  • 7Mortimer JE,Dehdashti F,Siegel BA,et al.Positron emission tomograpgy with 2-[18F] fluoro-2-deoxy-D-glucose and 16α-[18F] fluoro-17β-estradiol in breast cancer:correlation with estrogen receptor status and response to systemic therapy.Clin Cancer Res,1996,2(6):933-939.
  • 8Peterson LM,Mankoff DA,Lawton T,et al.Quantitative imaging of estrogen receptor expression in breast cancer with PET and 18F-fluorosetradiol.J Nucl Med,2008,49(3):367-374.
  • 9Oh SJ,Chi DY,Mosdzianowski C,et al.The automatic production of 16α-[18F] fluoroestradiol using a conventional[18F] FDG module with a disposable cassette system.Appl Radiat Isot,2007,65(6):676-681.
  • 10Kumar P,Mercer J,Doerkson C,et al.Clinical production,stability studies and PET imaging with 16-α-[18F] fluoroestradiol([18F] FES)in ER positive breast cancer patients.J Pharm Pharm Sci,2007,10(2):256s-265s.

引证文献7

二级引证文献36

中国肿瘤
2008年 第7期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部